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Background: China has become the world‘s second largest healthcare market based on a recent report by the
World Health Organization. Eventhough China achieved universal health insurance coverage in 2011, representing
the largest expansion of insurance coverage in human history achieved; health inequality remains endemic in
China. Lessons from the effect of market crisis on health equity in Europe and other places has reignited interest
in exploring the potential healthcare market aberrations that can trigger distributive injustice in healthcare
resource allocation among China’s provinces. Recently, many healthcare investors in China have become more
concerned about capital preservation, and are responding by abandoning long term investments strategies in healthcare.
This investment withdrawal en mass is perceived to be influenced by herding tendencies and can trigger or consolidate
endemic health inequality.
Methods: Our study simultaneously employs four testing models (two state spaced models and two return dispersion
models) to establish the existence of procyclical (herding) behavior among the stocks and its health equity implications.
These are applied to a large set of data to compare and contrast results of herd formation among investors in fourteen
healthcare sectors in China.
Results: The study reveals that apart from the cross sectional standard deviation (CSSD) model, the remaining two
models and our augmented state space model yields significant evidence of herding in all subsectors of the
healthcare market. We also find that the herding effect is more prominent during down movements of the market.
Conclusion: Herding behavior may lead to contemporaneous loss of investor confidence and capital withdrawal and
thereby deprive the healthcare sector of the much needed capital for expansion. Thus there may be obvious delay in
efforts to bridge the gap in access to healthcare facilities, medical support services, medical supplies, pharmaceuticals,
biotechnology, diagnostic substances, medical laboratory and advanced medical equipment across China. Moreover, a
potential crash in the healthcare market is possible in the healthcare sector as a result of persistent herding tendencies
among investors and that may have more damaging consequences for health inequality in China.
Keywords: Healthcare, Equity, Herding, Models, Stocks, Investors, China* Correspondence: zll62@ujs.edu.cn
1School of Management, Jiangsu University, 301 Xuefu Road, Zhenjiang,
Jiangsu, People’s Republic of China
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Lulin et al. International Journal for Equity in Health  (2016) 15:113 Page 2 of 15Background
According to [1] healthcare remains a very popular in-
vestment theme in developed markets especially those
with ever increasing ageing population, but the potential
impact is broader in Asia. Leading the Asian healthcare
renaissance is China due to uninterrupted economic
emancipation and intensified government’ effort to con-
struct the social safety nets needed to reduce excessive
inequality in access to healthcare in China and beyond
[2]. The prevalence of health inequality in China is
highlighted in several studies particularly in the recent
publications of the World Health Organization, Institute
for Health Economics of the Ministry of Health in China
and international and regional humanitarian agencies in-
cluding Medicine without Borders, the Red Cross Society
etc [3]. All of these studies present a gloomy report of a na-
tional healthcare sector that is skewed in favour of the rich
eastern provinces (Jiangsu, Shanghai, Guangdong, Zhejiang,
Shandong etc) relative to the poorer western provinces
(Tibet, Gansu, Xinjiang, Yunnan and Qinghai etc) [3].
In response to the 2011 Rio Summit on the Social
Determinants of Health (that recognized a pressing need
to take action to reduce health inequities), the Chinese
government has augmented its ongoing health system
reform (started in 2009) to improve equality, effective-
ness of public health functions and rejuvenated national
policies on health inequities [2, 4]. Predictably, China
achieved universal health insurance coverage in 2011,
representing the largest expansion of insurance coverage in
human history. This success was attained owing to strong
public support for government intervention in health care,
renewed political commitment from top leaders, heavy
government subsidies, fiscal capacity backed by China’s
economic power, healthcare financing and policy responsi-
bilities delegated to local governments and pragmatic
implementation strategy for health equality [5].
The gain notwithstanding, health inequality is far from
being eradicated in China. The 2015, China National
Health Equality Survey (as reported by [6]) shows that
the provincial disparity in infant and childhood mortality
(1:5), life expectancy (3:1), maternal mortality (1:4), doc-
tor to patient ratio (6:1), health insurance coverage (3:1)
and other indicators of health inequity favoured the
eastern provinces. The disparities extend beyond the
provincial level to include health inequity among mi-
grant and resident population and genders. Typical of
most equality induced healthcare reforms, China’s ap-
proach to bridging the gap has largely focused on
curbing disparities in health insurance coverage [7, 8],
legal barriers [9], structural barriers [10], dispropor-
tionate health care financing system [11], linguistic
barriers [12], health illiteracy [13], financial constrains
[14], demographic factors [15] and lack of healthcare
facilities and personnel [16].However lessons from the global economic crises
[17–19] and the euro debt crisis [20, 21] shows that
economic indicators such as exchange rate volatility,
interest rate volatility, stock market movements etc can
inherently induce other forces in the healthcare market
to exacerbate equity gaps or close them. In China, the
healthcare market has steadily attracted a lot of atten-
tion from investors (within and outside China) eyeing
countercyclical stories and demographic trends that are
less affected by the vagaries of currency risk and monetary
policy [22]. This is also in response to the growing oppor-
tunities in the sector as wealthier elites are willing to
spend more for better healthcare [1]. Despite the initial
sell-off in the early 2000s, China’s healthcare stocks as
measured by the MSCI China Health Care Index bounced
back substantially in mid 2002 following greater foreign
investment. This was also boosted by an increase in
medical supply arising out of the outbreak of zoonotic
infections such as the infamous severe acute respiratory
syndrome (SARS) which ravaged through China in 2003.
Other factors which sustained the upsurge in healthcare
stock prices over a considerable period of time include en-
hanced medical supply and profit from the outbreak of
the pathogenic avian influenza (H5N1) in 2007 and the
Haemagglutinin (1) and Neuraminidase (1) (H1N1) in-
fluenza in 2009 [23]. Thus the nearly 15 % healthcare
stock return achieved between 2003 and 2012 by China
was only equaled by the healthcare stocks in Japan
while health-care stocks around other Asian countries
remained lower or unchanged [24–26].
A 2015 report by CLSA Asia-Pacific Markets suggest
that a major part of China’s healthcare sector appeal is
largely because it has a lot of companies that produces
drugs and medical devices that are well-positioned to tap
the burgeoning domestic and global market. Additionally,
China has announced an ambitious reform to provide
95 % of the population with health insurance and spend
$125b (¥850b) on health-care improvements between
2015 and 2020 to stimulate demand in biopharmaceuticals
and medical devices. The country also seeks to drive 25 %
revenue growth in China’s pharmaceutical industry over
the next two years. Unlike other sectors such as banking,
telecommunications etc state-owned exert limited domin-
ance in the healthcare markets especially the market for
drug production and medical-devices in China and this is
making it easier for private-sector companies to make
a mark.
Another report by Templeton Asset Management is-
sued in September 2015 indicated that healthcare sector
companies such as Shandong Weigao Group Medical
Polymer Co (a Hongkong maker of medical equipment
such as syringes, blood bags and stents) is likely to see
growth in sales with China’s medical services expand,
but with additional upside from potential sales overseas.
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owned-Shanghai-listed researcher and producer of both
natural drugs and chemical drugs with new formulations
for use in orthopedics, neurology, gastroenterology and
hepatology expects more positive returns on investments.
Further, the Templeton Asset Management report posited
that with the Chinese increasing their surveillance and
quality control a lot of these saleable products in the do-
mestic healthcare sector will become saleable globally and
this will expand the market. Even though currently Chinese
health-care stocks are generally commanding premium
values to their peers in other emerging markets, a series of
market fluctuations occurring intermittently (and more
visibly between 2014 and 2015) in the Chinese healthcare
stock market suggest that the market is susceptible to in-
vestors procyclical or herding behaviours. According to
[27] a factor that recently pressured pharmaceutical and
healthcare stocks in China was an announcement by
China’s National Development and Reform Commission
ordering price cuts for certain drugs after a government re-
imbursement scheme for some drugs suddenly jumped up
price of healthcare products and subsequently healthcare
stocks.
With this directive, healthcare stocks in China slid by
about 6.4 % since the news broke in June, 2015, although
the CLSA (Asia’s leading independent brokerage and in-
vestment group) allayed the fears of investors by issuing
a note to claim that price control is unlikely to have any
significant impact on the main listed companies and
called the sell-off a buying opportunity. However, [28]
argues that as China’s economic growth rate begins to
tumble and the presence of strict regulations intensify,
many investors both individual and institutions have be-
come more concerned about capital preservation, and
are responding by abandoning long term investments
strategies in the healthcare sector. Some have also re-
duced the risk exposure and switched to safer asset clas-
ses with the intention of switching back as soon as the
market condition improves. Bohl et. al. [29] also explain
that the trend is escalating because investors are imitating
each other largely due to the strong social network which
has become an unrivaled heritage of the Chinese business
culture.
According to [30–32] generally investors’ tendency to
imitate the action of others in the economy is what the
whole concept of herd or procyclical behaviour is about.
This is a part or attribute of behavioural finance and
economics which remains a consistently advancing field
of interest in contemporary finance and economics. Un-
derstanding the ‘herding effect’ on the healthcare sector
is an important issue because endemic herding tenden-
cies can have destabilizing impacts on the healthcare
sector such as price synchronicity of stocks and health-
care products and services [33, 34] and even marketcrash [35]. Given the magnitude of dependence on health-
care, the impacts will spread to investment, employment
and equitable distribution of healthcare resources and ser-
vices [21] with its attendant consequences on social stability
indicators such as healthcare inequity.
Many prior studies on investor herding behavior have
reported different outcomes using different methodologies
such as the return dispersions among group of securities
and cross sectional standard (or absolute) deviations of
returns. For example contrary to the investor herding be-
havior based on the rational asset pricing theories and the
supporting empirical work of [36] other researchers such
as [37–40] found out that herding is not a significant con-
tributor to returns on securities during market recession.
These were based on studies conducted on equities in the
US, international equities, commodity futures traded on
European exchanges, Exchange Traded Funds and Chinese
stocks respectively. Using data from sixty highly capi-
talized stocks, [41] used a cross sectional standard devi-
ation study and found no evidence to suggest that foreign
investors are more likely to herd in Taiwan market than
domestic investors.
Weiner [42] extended the work of [43, 44] who employed
cross sectional variability of factor sensitivities (instead of
returns) and non-parametric methods respectively to ana-
lyse daily stock returns in South Korea. Weiner [42] rather
used a hybridity of parametric and non-parametric method-
ologies on daily stock returns and observed that herding
tendencies in crude oil and heating oil futures were not sig-
nificant. These studies are inconsistent with the test of herd
behavior in the domestic loan market by [45] that ex-
tended the LSV herding measure proposed by [46]
within a Japanese market. On the whole, the empirical
evidence of herd behavior in the extant literature pro-
vides a general indication of the fact that stock markets
in general and China in particular are less information-
ally efficient relative to the efficient market hypothesis
hence the need for a study that extends the applicability
of the market efficiency hypothesis. This is because the
existence of herd formation will be a clear indicator of
violation of the assumptions for an efficient market in
which prices fully and instantaneously reflect all avail-
able information.
Our study seeks to explore the presence of herd be-
havior within the healthcare industry in China due to its
possible negative consequences for the healthcare mar-
ket in terms of investor interest, prices of healthcare
products and services which have repercussions for sus-
tainable healthcare in China and beyond.
General studies on how herding behavior as an informa-
tion aggregation mechanism influences decision making
process in China is also amply represented in the current
literature. For example [47] explored the neural and psy-
chological basis of herding in purchasing books online
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sity in China while [48] examined the influence of herd
behavior in C2C e-commerce in China. The closest appli-
cation of herding behavior in the healthcare sector are all
outside China and are equally intended to explore its use-
fulness as information gathering mechanism for decision
making which is sometimes at variance with the evidence
based decision making process. For example [49] explores
herding behavior as a psychosocial factor in quarantine
during epidemic and how it can help ensure successful
control while, [50] has applied herding behavior to how
hospitals can form strategic groups in order to remain
stable. Using a game-theoretical reflections [51] empiric-
ally validates the view that herding behavior can be used
to appeal to free-riders to adopt pro-social behaviours in
vaccine advocacy. Similarly, herding behavior is tested by
[52] as a strategic management concept that can be
used for hospital leadership and management while
[53] identifies the negative aspects of herding behavior
as an information aggregation system in healthcare
relative to evidence based medicine. He warns health-
care institutions not to rush to implement policies and
programs by merely following what contemporaries are
doing. While all of the above studies have taken place
outside China, these ground breaking attempts to draw
on a field once thought to be purely economics and fi-
nance to the administration of mainstream healthcare is
inspirational hence our attempt to advance the frontiers of
the application of herding behavior in the healthcare sec-
tor by focusing on healthcare stock market and its poten-
tial implication for the whole healthcare market in China.
With respect to studies about herding behavior in the
stock markets, our study is necessary in the light of
limited studies on industry specific herd behavior in
China and the conflicting evidence of their outcome [54]
and [55] as well as the differences in the variables used
in constructing and testing models [31]. To the best of
our knowledge, the most recent effort at studying herding
behavior in a specific industry in China are by [56] and
[57] who focused on herding behavior in the housing in-
dustry in China. In both cases they employ different set of
methodologies (least squares method and quantile re-
gression method) which are totally different from those
employed in this study. We extend the frontiers of
current knowledge from the general (market) to the
specific (industry) by empanelling and testing an ensemble
of more sophisticated analytical models from the extant
literature (cross sectional standard deviations-CSSD and
cross sectional absolute deviations-CSAD on Chinese
healthcare stock market. The results are then compared
with our augmented State Space Model (which we call
State Space Model 2) which is an enhancement on the
existing State Space Model (which we call State Space
Model I) in order to examine their respective statisticalpowers and subsequent robustness of inference. Under-
standing which models (summarized in the next section)
yield herding behavior may provide information about the
ways in which investors herd, the subsector with the great-
est susceptibility to herding and its impact on health
equity in particular and healthcare policy as a whole.
We follow the daily equally-weighted index returns data
from healthcare stocks on three stock markets in China
(including HongKong) namely the Shenzhen, Shanghai
and Hongkong where domestic investors rather than insti-
tutional account for the highest percentage of total invest-
ment. This helps to overcome the weaknesses of using
only firm level data within the market portfolio [58]. This
may answer an important question posed by [59]; who
expressed uncertainty as to whether herd formation would
more likely occur at the level of investment in stock
groups (such as stocks in an industry) where investors face
similar decision problems and can observe the behaviour
of others in the group (see also [60]). Further the market
has seen tremendous interest by foreign investors. Because
domestic individual investors usually lack the professional
knowledge and skill to access accurate information easily
[54, 60, 61], the resulting information asymmetry may
encourage such individual investors to follow the actions
of the crowd including more informed institutional and
foreign investors especially in high collectivist culture such
as China.
Therefore it is not out of place for one to expect the
formation of investor herds in this market dominated by
the less informed domestic individual investors [58, 61].
For this purpose, it is especially interesting to examine
whether herd formation exists in the healthcare sector of
the Chinese stock market with this unique characteristic.
Following [61], we also employ two major different testing
methodologies based on the dispersions of returns and
factor sensitivities. The inferences are then compared
from each model using a large scale data from the health-
care market in China. After presenting out data and em-
pirical results we conclude the paper by healthcare market
and policy implications before proposing future research
direction.
Methods
This study used four testing models (two state spaced
models and two return dispersion models) to establish
the existence of procyclical (herding) behavior among the
stocks. The operationalisation of each of these models are
briefly explained in the next section.
Return dispersion models
In the return dispersion models either a cross section
absolute deviation (CSSD) or a cross-sectional absolute
standard deviations (CSAD) of the individual returns of
the firm within groups of securities is used. The first
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presented by [37] who used the CSSD to measure the
average proximity of returns of individual asset to the re-
alized market average. Similarly a non-linear regression
specification of the CSAD has been used by [38, 39, 62]
to examine how the level of equity return dispersions
relates to the overall market return. Other studies which
have successfully used the CSAD approach in herd be-
havior measurement (albeit differences in markets) in-
clude [26, 40, 41, 60, 61]. Similar to these earlier
studies, we measure return dispersion using CSSD as
formulated below:
CSSDt ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
XN
i¼1
ri;t−rp;t
 2
N−1
vuuuut ð1Þ
In which case n represents the number of firms in the
aggregate market portfolio while ri,t represents the stock
return observed on firm i for day t and rp,t is the cross-
sectional average of the n returns in the market portfolio
for day t. This measure also represents the individual se-
curity return dispersion around the market average. The
fundamental idea in this model is based on the argument
that herd behavior prevents security returns from deviat-
ing far from the overall market return. This is because
of the assumption that individuals are likely to suppress
their personal beliefs and invest solely on the basis of
collective actions of the market. Using the rational asset
pricing models however give a different prediction that
suggest that dispersions increases with changes in the
absolute value of market return. This is because it is as-
sumed that each asset is different as far as sensitivity to
the market return is concerned. Additionally this model
also implies that herd behavior may likely occur when
market movements become extreme because they will
usually go with the market consensus during such pe-
riods. Thus the behavior of the dispersion measure in (1)
during periods of market stress is examined by estimating
the following linear regression model:
CSSDt ¼ αþ βDDLt þ βUDUt þ εt ð2Þ
where Dt
L = 1, if the aggregate market portfolio return on
day t lies in the lower tail of the return distribution; 0
otherwise, and Dt
U = 1, if the aggregate market portfolio
return on day t lies in the upper tail of the return dis-
tribution; 0 otherwise. Despite a concern that this may
be arbitrary, this is supported in the current literature
[54, 56, 59] where extreme market return is defined a
return lying between one to five percent lower or upper
tail of the return distribution. Moreover, the dummies
in Eq. (2) seek to capture the return dispersion differ-
ences in periods of extreme market movements. Sincethe formation of herd behavior implies conforming to
the market consensus, the presence of negative and
statistically significant βD (for down markets) and βU
(for up markets) coefficients gives an indication of herd
behavior among the market participants.
The second return dispersion used in this study is pro-
posed by [38] who also employ the cross-sectional abso-
lute deviation of returns (CSAD) to measure return
dispersion. CSAD and this is expressed as:
CSADt ¼ 1N
XN
i¼1
ri;t−rm;t
  ð3Þ
Chang et. al. [38] as reported by [61] is unconvinced
about the assumptions of CAPM and suggest that return
dispersions increases relative to increases in market re-
turn hence their relationship is linear. Proponents of the
CAPM assumption of linearity argue that if a significant
non-linear effect exist, then the results of the cross sec-
tional standard deviations of result would not be valid.
However, [38] challenges this assertion and demonstrates
that in periods of economic or market stress, there is
some likelihood of a non-linear relationship between re-
turn dispersions and market return (either a decline or
increase). Following the example of [38] and other op-
ponents of the CAPM assumptions, a testing model is
proposed based on a general quadratic relationship between
CSADt and rm,t of the form:
CSADt ¼ αþ γ1 rm:tj j þ γ2r2m:t þ εt ð4Þ
With this model, the evidence of herd behavior will
show by the less than proportional or low increases in
the cross-sectional absolute deviation (CSAD) when
there is extreme market movement. In that case herding
formation will show by a negative and statistically sig-
nificant non-linear coefficient γ2 and vice versa.
State space models
The next model used for testing herding behavior in this
study is the state space model which was first proposed
by [43]. Instead of focusing on returns to measure herd-
ing behavior, the focus is rather on the cross-sectional
variability of factor sensitivities. Using a single factor
model based on the market return, Hwang and Salmon
[43] formulated a measure of herding behavior using the
relative dispersion of the betas for all assets within the
market as follows:
Er ritð Þ ¼ βimtEt rmtð Þ ð5Þ
where rit and rmt are the excess returns on asset i and
the market at time t, respectively, βimt is the systematic
risk measure, and Et(⋅) is conditional expectation at time
t. In equilibrium, only β is needed to price an asset i.
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for equilibrium relationship of Eq. (5) hence trade to
match the return of individual assets with that of the
market. This gives a bias β term and expected rate of re-
turn reflecting the matching of individual asset returns
with that of the market. Thus with CAPM, the presence
of herding behavior means that the real β coefficient
obeys Eq. (6) by replacing Eq. (5) as follows:
Ebt ritð Þ
Et rmtð Þ ¼ β
b
imt ¼ βimt−hmt βimt−1
 
; ð6Þ
where Et
b(rit) and βimt
b are the market’s biased short run
conditional expectation on the excess returns of asset i
and its beta at time t, and hmt is a latent herding param-
eter that changes over time, hmt ≤ 1, and conditional on
market fundamentals. In general, [61, 63] argues that
when (0 < hmt < 1), then some degree of herding exist in
the market but the intensity depends on the magnitude
of hmt. Since the form of herding behavior being dis-
cussed is a market-wide behavior and it is assumed that
Eq. (6) holds for the total assets in the market, the level
of herding can be estimated with the total assets in the
market instead of a single asset and this removes the ef-
fects of idiosyncratic movements in any individual βimt
b .
The standard deviation of βimt
b is then formulated as
Stdc β
b
imt
  ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Ec βimt−hmt βimt−1
 
−1
 2 r
¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Ec βimt−1
 2 r
1−hmtð Þ
¼ Stdc βimt
 
1−hmtð Þ;
ð7Þ
where Ec(⋅) represents the cross-sectional expectation.
Taking the logarithm of Eq. (7) and assuming that
Stdc(βimt
b ) can be time-varying over a time interval in re-
sponse to the level of herding in the market, we rewrite
Eq. (7) as
log Stdc β
b
imt
  	 ¼ μm þ υmt
where μm = E[log[Stdc(βimt)]] and υmt ∼ iid(0, σmυ
2 ). State
Space Model 1 is then estimated as
log Stdc β
b
imt
  	 ¼ μm þ Hmt þ υmt; ð8Þ
Hmt ¼ ϕmHmt−1 þ ηmt ; ð9Þ
where Hmt = log(1 − hmt) and ηmt ∼ iid(0, σmη
2 ). Equations
(8) and (9) are the standard state-space model with
Kalman filter estimation. In this model, the focus is ba-
sically on the dynamism in the movement patterns in
the latent state variable, Hmt, the state equation. When
σmη
2 = 0, then no evidence of herding behavior is observedand that means that Hmt = 0 for all t. With this model a
dynamic process of herding, Hmt is allowed to evolve over
time. If the value of σmη
2 is significant, then it mean there
exist herding and a significant ϕ implies the validity of this
autoregressive structure. Alternatively [61] argues that it is
possible formulate an augmented model when market
volatility log σmt is added to Eq. (8) and return, rmt, as in-
dependent variables leading to State Space Model 2 for-
mulated as
log Stdc β
b
imt
  	 ¼ μm þ Hmt þ cm1 logσmt
þ cm2rmt þ υmt
ð10Þ
Similarly, a significant value of σmη
2 can be interpreted
as the existence of herding and a significant ϕ supports
this particular autoregressive structure.
Data and empirical results
The study used a dataset containing the average daily
returns of 399 stocks from 14 subsectors of the healthcare
industry by CLSA and trading on three stock markets
namely Shenzhen, Hongkong and Shanghai between July
2004 and June 2014. Each of these stocks is further sub
classified into one of 14 subcategories of the healthcare sec-
tor (healthcare facilities, medical equipment manufacture,
medical supplies & distribution, pharmaceuticals diversified,
pharmaceuticals generic and specialty, biotechnology,
managed health care, diagnostic substances, medical
laboratory and research, advanced medical equipment
manufacture, healthcare transportation, therapeutic medi-
cine, medical tourism and other medical support services)
as shown in Table 1. This helps to verify whether a group
is more likely to herd if trade is sufficiently homogeneous,
i.e. each member faces a similar decision problem, and
each member can see the trades of other group members
[59]. As the years 2004, 2009 and 2014 witnessed periods
of rapid foreign investment in Chinese healthcare market
(because of policy incentives), data for the periods and
share of foreign investment in all subsectors is highlighted.
This is because the presence of foreign investors is seen as
a significant precursor to herd formation [63]. The portfo-
lio returns based on an equally weighted portfolio of all
companies in the respective subsectors were then calcu-
lated. The information in Table 2 shows the summary sta-
tistics for average returns daily log, return dispersion and
the average number of companies used to calculate these
statistics for each sub-sector. Since the number of shares
in a sector does not remain constant over time, the table
shows the average number of companies during the sam-
pling period in the second column of the table. Panel A
shows that the average daily returns for all subsectors are
positive. Other medical support services (4.184) and
medical tourism (4.106) subsectors have the highest
Table 1 Shareholding percentage of market participants by sector (%)
Year Domestic
individual
Domestic
institution
Foreign
investor
Domestic
individual
Domestic
institution
Foreign
investor
Domestic
individual
Domestic
institution
Foreign
investor
Healthcare facilities Medical equipment manufacture Medical supplies & distribution
2004 90.44 0.87 7.80 90.14 0.64 9.14 81.58 0.47 15.95
2009 94.64 0.80 3.57 92.62 0.55 5.84 81.89 0.52 14.60
2014 75.42 0.91 23.67 64.99 0.90 34.11 82.54 0.54 16.93
Pharmaceuticals diversified Pharmaceuticals generic and specialty Biotechnology
2004 89.24 1.91 6.85 90.83 0.33 5.84 86.67 0.75 12.58
2009 94.74 3.17 1.09 95.64 0.72 2.64 93.29 0.40 2.31
2014 60.94 1.58 27.49 94.39 0.28 4.33 88.64 0.83 9.53
Managed health care Diagnostic substances Medical laboratory and research
2004 85.85 2.17 11.98 90.44 0.87 7.80 88.49 1.09 9.43
2009 85.98 2.97 11.05 94.64 0.80 3.57 85.87 1.47 11.67
2014 72.95 1.45 25.61 75.42 0.91 23.67 81.50 0.97 14.53
Advanced medical equipment manufacture Healthcare Transportation Therapeutic Medicine
2004 88.49 1.09 9.43 86.02 2.03 9.96 85.84 0.57 11.59
2009 85.87 1.47 11.67 89.93 1.93 6.15 90.67 0.55 7.78
2014 81.50 0.97 14.53 81.26 2.42 14.32 77.43 0.66 18.91
Medical Tourism Other Medical Support services
2004 85.85 0.64 9.14 91.90 1.46 6.64
2009 85.98 0.55 5.84 95.74 0.55 4.72
2014 62.95 0.90 34.11 87.80 1.89 10.41
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viation of average daily returns. Panel B of Table 2
shows the summary statistics for daily cross sectional
standard deviations within each subsector. In line with
the results of Panel A, we observe higher volatility
cross section in medical tourism.
Results of return dispersion models
Table 3 is the results of estimates for the CSSD base
model in equation 2. Given the significant changes in
dispersion and strong correlation, all estimates are made
using the Newey-West heteroskedasticity and autocor-
relation consistent standard errors. The MSCI China A
Healthcare Index was used to represent the market and
the upper and lower one and five percentile of the mar-
ket return was used to represent periods of market
stress. The regression output shows a negatively signifi-
cant parameter estimate (βD) for medical tourism sub-
sector at 99 % confidence interval. On the contrary the
parameter estimates for medical equipment manufacture
subsector, and specialty, managed healthcare and other
medical support service is significantly positive (99 %
confidence interval). The parameter estimates for phar-
maceuticals generic and therapeutic medicine is signifi-
cantly positive at 90 % confidence interval and theremaining sectors are positive but insignificant. Thus
generally (except medical tourism) cross-section stand-
ard deviation tends to be higher during periods of ex-
tremely down markets. This suggests that the included
stocks do not move in the same direction as the market
during periods of market stress but rather deviate more
from general market movements when the market takes
an extreme fall. Consistent with the work of [62], this
observation does not support herding.
In Table 4 the estimates for the model based CSAD
non-linear equation 4 has been presented. Similar to
[38], three distinct regressions were run for each subsec-
tor: one that uses the entire sample, and two limiting the
data to up (or down) movement of the market index.
Running separate models in this way allows us to exam-
ine if there is any asymmetric effect of herd behavior.
The results from the non-linear model give completely
different results than the first method. Table 4 again
shows that the first nonlinear term (γ2) is statistically
significant in almost all subsectors. It is very instructive
to note that unlike the linear model, the R2 values of the
nonlinear regression models are generally higher than
those of the linear model. This indicates that the non
linear regression fits better than the linear regression in
Table 3 as the proportion of the variance in herding that
Table 2 Summary statistics: average daily returns and cross-sectional standard deviations
Industry No. of firms Observation Mean return Std. Dev
Panel A: average daily return
Healthcare facilities 48 3990 0.016 % 2.457 %
Medical equipment manufacture 48 3990 0.026 2.404
Medical supplies & distribution 25 3990 0.028 2.745
Pharmaceuticals diversified 44 3990 0.014 2.774
Pharmaceuticals generic and specialty 44 3990 0.040 2.506
Biotechnology 14 3990 0.021 2.670
Managed health care 25 3990 0.045 2.476
Diagnostic substances 28 3990 0.004 4.019
Medical laboratory and research 41 3990 0.017 2.707
Advanced medical equipment manufacture 21 3990 0.044 2.827
Healthcare Transportation 4 3990 0.044 2.724
Therapeutic Medicine 9 3990 0.056 2.112
Medical Tourism 4 3990 0.056 4.106
Other Medical Support services 44 3990 0.051 4.184
Panel B: cross-sectional standard deviation
Healthcare facilities 1.558 % 0. 911 %
Medical equipment manufacture 1.989 0.705
Medical supplies & distribution 1. 995 0.725
Pharmaceuticals diversified 2.119 0.609
Pharmaceuticals generic and specialty 2.015 0.649
Biotechnology 1.958 0.790
Managed health care 1.924 0.649
Diagnostic substances 2.199 1.094
Medical laboratory and research 1.690 0. 915
Advanced medical equipment manufacture 1.917 0.746
Healthcare Transportation 1.914 0. 944
Therapeutic Medicine 1.405 0. 999
Medical Tourism 2.444 0.920
Other Medical Support services 2.424 0.740
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Generally, the information indicates that the inference
made from the linear model disclosed in Table 3 may be
spurious. Thus we rely heavily on evidence from the non-
linear test in Table 4 to make inferences about herding. In
that regard, evidence of herd formation is found in all the
subsectors and regressions yield statistically significant
and negative estimates γ2 which indicates a declining non-
linear relationship between the market return and equity
return dispersions. The results of regression analysis per-
formed with respect to up and down markets separately
show herding effect is mostly prominent in market losses.
The results suggest that herd formation is most likely ob-
served during periods of market losses.Results of state space models
The information in Table 5 presents the results of the
State Space Model 1. The results show strong evidence
of herding through Hmt and this is consistent with the find-
ings using the non-linear model. It is observed that Hmt is
highly persistent with large and significant values of ϕ^m .
Moreover σmη estimates are highly significant and indicate
herd behavior. On the other hand, Table 6 show results of
the augmented State Space Model 2 which contains two
market variables (market return and market volatility). If
these two are added in the measurement equation, it allows
us to analyze the degree of herding, given the state of the
market. In that regard, the findings are similar to that of
the State Space Model 1 shown in Table 5.
Table 3 Regression coefficients for CSSDt = α + βDDtL + βUDtU + εt (R2-values in parentheses)
Return dispersions Market return in the extreme upper/lower 1 % of
the return distribution
Market return in the extreme upper/lower 5 % of the
return distribution
Subsector α βD βU α βD βU
Healthcare facilities 1.554 % 0.145 % 0.194 %** 1.527 % 0.454 %*** 0.169 %***
(0.586) (0.649) (0.573) (0.724)
Medical equipment manufacture 1.857 0.699*** 0.442*** 1.724 0.541*** 0.451***
(0.830) (0.828) (0.979) (0.681)
Medical supplies & distribution 1.794 0.167 0.026 1.757 0.497*** 0.160***
(0.549) (0.520) (0.570) (0.524)
Pharmaceuticals diversified 2.116 0.146 0.149* 2.090 0.449*** 0.142***
(0.669) (0.596) (0.738) (0.665)
Pharmaceuticals generic and specialty 2.009 0.144* 0.404*** 1.970 0.402*** 0.175***
(0.684) (0.549) (0.949) (0.693)
Biotechnology 1.955 0.079 0.016 1.927 0.422*** 0.147***
(0. 638) (0.742) (0.561) (0.563)
Managed health care 1.919 0.479*** 0.044 1.790 0.476*** 0.194***
(0.915) (0.671) (0.563) (0.899)
Diagnostic substances 2.196 0.079 0.176 2.162 0.441*** 0.404***
(0. 908) (0.695) (0.539) (0.921)
Medical laboratory and research 1.691 −0.0002 −0.074 1.670 0.407*** 0.099
(0.826) (0.750) (0.570) (0.537)
Advanced medical equipment manufacture 1.914 0.076 0.165 1.771 0.404*** 0.414***
(0.827) (0.619) (0.599) (0.636)
Healthcare Transportation 1.916 0.061 −0.119* 1.776 0.456*** 0.114*
(0.612) (0.853) (0. 618) (0.808)
Therapeutic Medicine 1.495 0.492* 0.569*** 1.467 0.479*** 0.175***
(0.971) (0.520) (0.798) (0.971)
Medical Tourism 2.440 −0.479*** −0.475*** 2.419 0.069 −0.012
(0.949) (0.911) (0.736) (0.568)
Other Medical support services 2.067 0.447*** 0.110*** 2.041 0.417*** 0.121***
(0.806) (0.663) (0.793) (0.949)
(***, ** and * denote statistical significance at 1, 5 and 10 % respectively)
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turn are accounted for, the term Hmt remains significant
when the two explanatory variables are included. The
findings indicate that herding behavior could explain
changes in the volatility of factor sensitivities or disper-
sion of the betas for all assets in the market (Stdc(βimt
b ),
instead of changes in fundamentals. Moreover positive
and significant coefficients for the term log σmt were es-
timated for most of the stocks in subsectors in the
healthcare industry and that indicates an increasing dis-
persion of the betas for all assets in the market (Stdc(βimt
b )
with market volatility. This result is equally consistent
with the previous studies that suggest that herding is more
likely to occur during periods of market stress, i.e. highlyvolatile periods. Similarly, Table 6 shows that subsectors
such as healthcare facilities, medical equipment manufac-
ture, pharmaceuticals diversified, biotechnology, diagnos-
tic substances and healthcare transportation sub sectors
have dispersion of the betas for all assets in the market
(Stdc(βimt
b ) that increases as market volatility rises since
the coefficients for the market volatility term (log σmt)
have significant and positive values. It is worth noting
from Table 1 that that these subsectors (healthcare facil-
ities, medical equipment manufacture, pharmaceuticals di-
versified, biotechnology, diagnostic substances) are among
those that have seen increase in foreign shareholding pres-
ence between 2004 and 2014. This gives credence to the
view of [63, 64] that foreign investors may exhibit herding
Table 4 Regression coefficients for CSADt = α + γ1|rm. t| + γ2rm. t2 + εt (R2-values in parentheses)
Absolute deviation Whole sample Down market (Rm < 0) Up market (Rm > 0)
Industry α γ1 γ2 α γ1 γ2 α γ1 γ2
Healthcare facilities 1.016 0.162*** −0.017*** 1.002 0.117*** −0.029*** 1.046 0.095** −0.004
(.799) (.534) (.831) (.727) (.695) (.856)
Medical equipment manufacture 1.196 0.194*** −0.014** 1.174 0.165*** −0.024*** 1.121 0.117*** 0.0004
(.860) (.841) (.849) (.835) (.802) (.823)
Medical supplies & distribution 1.111 0.404*** −0.044*** 1.177 0.471*** −0.056*** 1.146 0.121*** −0.029***
(.789) (.685) (.895) (.869) (.827) (.820)
Pharmaceuticals diversified 1.494 0.129*** −0.040*** 1.470 0.171*** −0.049*** 1.421 0.169*** −0.017***
(.672) (.674) (.851) (.812) (.813) (.821)
Pharmaceuticals generic and specialty 1.424 0.106*** −0.022*** 1.407 0.157*** −0.042*** 1.445 0.144*** −0.009
(.725) (.851) (.703) (.805) (.668) (.811)
Biotechnology 1.196 0.195*** −0.027*** 1.177 0.157*** −0.049*** 1.421 0.122*** −0.014
(.722) (.847) (.802) (.637) (.804) (.773)
Managed health care 1.144 0.142*** −0.040*** 1.109 0.420*** −0.042*** 1.160 0.161*** −0.017***
(.703) (.840) (.822) (.645) (.731) (.819)
Diagnostic substances 1.545 0.101*** −0.024** 1.551 0.146*** −0.044** 1.544 0.145*** −0.009
(.846) (.824) (.665) (.725) (.696) (.822)
Medical laboratory and research 1.124 0.104*** −0.046*** 1.105 0.157*** −0.044*** 1.144 0.146*** −0.027***
(.837) (.811) (.736) (.666) (.773) (.766)
Advanced medical equipment manufacture 1.154 0.141*** −0.029*** 1.155 0.402*** −0.044*** 1.155 0.149*** −0.011
(.660) (.875) (.748) (.812) (.768) (.812)
Healthcare Transportation 1.147 0.171*** −0.045*** 1.141 0.447*** −0.057*** 1.166 0.194*** −0.044***
(.860) (.651) (.806) (.805) (.745) (.725)
Therapeutic Medicine 0.924 0.125*** −0.007 0.771 0.124*** −0.027*** 0.977 0.002 0.020**
(.894) (.749) (.783) (.839) (.637) (.762)
Medical Tourism 1.597 0.175*** −0.057*** 1.577 0.194*** −0.060*** 1.617 0.157*** −0.057***
(.564) (。627) (.807) (.890) (.757) (.826)
Other Medical support services 1.446 0.192*** −0.017*** 1.426 0.147*** −0.024*** 1.465 0.147*** −0.012*
(.590) (.628) (.636) (.642) (.734) (.857)
(***, **, and * denote statistical significance at 1, 5, and 10 %, respectively)
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Comparing the estimates for ϕ^m across subsectors, it is
noted that the effect of herd behavior in medical tourism
and other medical support services are relatively higher
than the other subsectors. From Table 1 it is observed that
the medical tourism and other medical support services
have seen significant increase in foreign investors since
2004 and this can be the source of the herding behavior.Discussion of findings
We sought to extend testing of herd behavior of inves-
tors to the healthcare stock market in China based on
firm-level data on several healthcare related enterprises
operating in 14 subsectors of the healthcare market. In
addition, we simultaneously employ different models ofherding at a large set of data to compare and contrast
results to contextually test how these different ap-
proaches yield different or similar results of herd forma-
tion among investors. We found most of the models
yielding evidence of endemic herding behavior in most
of the healthcare subsectors in China. As indicated in
the introductory section, there is enormous literature
that supports the destabilizing effect of herd behavior in
a sector including the healthcare sector. For example the
effect of ‘herding’ on stock price synchronicity as sug-
gested by [33, 34, 63] threatens distributive justice in
healthcare resources in the sense that herding tendencies
can stimulate sharp fluctuation in the prices of health-
care stocks en masse.
This may lead to contemporaneous loss of investor con-
fidence and capital withdrawal (see Akerlof and Shiller’s
Table 5 State space model 1 (R2-values in parentheses) log[Stdc(βimtb )] = μm + Hmt + υmt and Hmt = ϕmHmt − 1 + ηmt
Industry μm ϕm σ
2
mυ σ
2
mη
Healthcare facilities −0.675*** 0.940*** 0.075*** 0.099***
(.760) (.791) (.817) (.549)
Medical equipment manufacture −0.645*** 0.940*** 0.019*** 0.091***
(.901) (.249) (.543) (.651)
Medical supplies & distribution −0.570*** 0.945*** 0.047*** 0.091***
(.861) (.521) (.672) (.621)
Pharmaceuticals diversified −0.647*** 0.957*** 0.040*** 0.067***
(.747) (.894) (.617) (.549)
Pharmaceuticals generic and specialty −0.697*** 0.914*** 0.054*** 0.114***
(.651) (.913) (0.572) (.781)
Biotechnology −1.456*** 0.927*** 0.015*** 0.064***
(.710) (.592) (.169) (549)
Managed health care −0.657*** 0.954*** 0.025*** 0.071***
(.628) (.084) (.095) (.067)
Diagnostic substances −0.577*** 0.919*** 0.072*** 0.142***
(.801) (.667) (.074) (.588)
Medical laboratory and research −0.709*** 0.792*** 0.070*** 0.165***
(.570) (.595) (.684) (.762)
Advanced medical equipment manufacture −0.707*** 0.949*** 0.047*** 0.104***
(.590) (.748) (.656) (.565)
Healthcare Transportation −0.727*** 0.905*** 0.100*** 0.165***
(.755) (.656) (.524) (.671)
Therapeutic Medicine −0.457*** 0.920*** 0.022*** 0.072***
(0.531) (.675) (4.400) (.893)
Medical Tourism −1.172*** 0.997*** 0.047*** 0.054***
(.741) (.667) (.523) (.974)
Other Medical support services −1.474*** 0.916*** 0.075*** 0.091***
(.518) (.571) (.732) (.591)
(***, **, and * denote statistical significance at 1, 5, and 10 %, respectively)
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animate economic behavior) and thereby deprive the
healthcare sector of the much needed capital for expan-
sion. Thus there may be obvious delay in efforts to bridge
the gap in access to healthcare facilities, medical support
services, medical supplies, pharmaceuticals, biotechnology,
diagnostic substances, medical laboratory and advanced
medical equipment across China. Consistent with the
work of [5] this may be a major challenge in China where
inner (western) and some northern provinces, rural areas,
and communities with high concentrations of minority
populations have limited access to medical care due to the
scarcity of primary care practitioners, facilities, medical
supplies, poor transportation and poor communication.
Evidence of this challenge may be inferred from the
decisions of renowned listed healthcare companies such
as Jiangsu Hengrui Med Co, Kangmei Pharmaceutical,Yunnan Baiyao Group Co, Dong E E Jiao Co, Tasly
Pharmaceutical, Shanghai Raas Blood, Searainbow Hld
Corp, Tonghua Dongbao Pharma, Shanghai Fosun Pharma,
Beijing Tongrentang to close down production facilities or
suspend expansion into western provinces such as Tibet,
Gansu, Xinjiang, Yunnan and Qinghaid due to capital chal-
lenges [4]. This in no small way threatens equitable access
to quick and affordable pharmaceutical and other health-
care products by the companies as the over 300,000 clinics,
pharmacies and hospitals across the Western provinces that
get supply from these facilities must resort to supply from
other provinces [4].
Moreover, a potential crash in the healthcare market is
possible in the healthcare sector as a result of persistent
herding tendencies among investors and that may have
more damaging consequences for health inequality in
China. Consistent with evidence adduced by [14, 35]
Table 6 State space model 2 (R2-values in parentheses) log[Stdc(βimtb )] = μm + Hmt + cm1 log σmt + cm2rmt + υmt and Hmt = ϕmHmt− 1 + ηmt
Industry μm ϕm σ
2
mυ σ
2
mη log σmt rmt
Healthcare facilities 0.451*** 0.941*** 0.075*** 0.097*** 0.659*** −0.005
(.569) (.542) (0.903) (.820) (.659) (.580)
Medical equipment manufacture 0.879*** 0.941*** 0.019*** 0.091*** 0.672*** 0.005
(.816) (.509) (.785) (.690) (.053) (.614)
Medical supplies & distribution −0.747*** 0.944*** 0.047*** 0.091*** −0.151*** 0.046
(.739) (.600) (.0523) (.875) (.532) (.518)
Pharmaceuticals diversified 0.897*** 0.957*** 0.040*** 0.067*** 0.776*** 0.027
(.846) (.697) (.817) (.647) (.557) (.657)
Pharmaceuticals generic and specialty −0.706*** 0.914*** 0.054*** 0.114*** −0.057*** −0.069
(.847) (.684) (.710) (.567) (.769) (.739)
Biotechnology 1.447*** 0.917*** 0.015*** 0.064*** 1.657*** 0.047
(.542) (.910) (.812) (.536) (.566) (.588)
Managed health care −1.627*** 0.950*** 0.024*** 0.072*** −0.545*** 0.026
(.814) (.596) (.640) (.714) (.984) (.717)
Diagnostic substances 1.440*** 0.917*** 0.072*** 0.142*** 1.092*** −0.067
(.586) (.635) (.671) (.812) (.938) (.814)
Medical laboratory and research −2.479*** 0.792*** 0.070*** 0.164*** −0.970*** −0.092
(.701) (.598) (。673) (.530) (.633) (.636)
Advanced medical equipment manufacture −1.470*** 0.945*** 0.047*** 0.104*** −0.429*** 0.029
(.782) (.609) (.795) (.618) (.598) (.814)
Healthcare Transportation −0.471*** 0.907*** 0.100*** 0.165*** 0.111*** 0.006
(.657) (.740) (.561) (.767) (.840) (.733)
Therapeutic Medicine −0.541*** 0.919*** 0.021*** 0.072*** −0.047*** 0.017
(.556) (.592) (.542) (.642) (.870) (.543)
Medical Tourism 0.471 0.997*** 0.047*** 0.054*** 1.022* 0.007
(.748) (.538) (.640) (.539) (.529) (.626)
Other Medical support services −0.547*** 0.954*** 0.074*** 0.095*** 0.014 0.147
(.512) (.719) (.976) (.529) (.944) (.727)
(***, **, and * denote statistical significance at 1, 5, and 10 %, respectively)
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healthcare products, black marketeering of strategic
healthcare products and unemployment. In China where
the healthcare sector employs approximately 12 % of the
low income population, the resulting loss of jobs from a
health market crash may lead to high cost of healthcare
products and services which can fuel income barriers to
health equity.
Thus, our findings may explain one of the reason why
behavioral economist Richard Thaler thinks that the un-
sophistication and extrapolation biases in decision
among Chinese healthcare investors and companies as
well as unguarded response by the government makes a
healthcare market crash in China potentially unprece-
dented in scale [16]. Similarly, the contribution of the
Chinese healthcare sector to the global healthcare industry
means that any aberrations can have a negative spillovereffect and compound the already precarious health in-
equality in Asia, Africa and countries that substantially de-
pends on China for healthcare services and products.
For example between 2000 and 2014, 34 % of health-
care supplies to member countries of the ASEAN came
from China while 57 % percent in Africa came from
China. If herding induced market crash leads to a reduc-
tion in inflow of medical services, products and equip-
ments to these countries, there is a greater tendency to
perpetuate inequity in healthcare in these countries [65].
This stems from the fact that consequential scarcity of
healthcare resources will lead to disproportionate alloca-
tion of few resources to China dependent countries.
Coupled with the expected increase in the cost of the
available healthcare resources such as drugs and other
supplies (due to scarcity), the resulting high cost of
healthcare may likely be monumental as most of these
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heavy economic challenges at both national and individual
level. The effect on global and regional health inequity is
thus unlikely to be insignificant.
Consistent with previous studies, these findings elicit
serious policy response to ameliorate any potential
harmful effect of herding behavior on health equity in
both China and other China dependent countries. Simi-
lar to the heavy involvement of Chinese government in
the business sector, our analysis support the views of [9]
of the necessity for the state to provide a greater propor-
tion of public funding for health so that health care
provision is not at the peril of private, for profit inter-
ests. This will reduce the impact of potential withdrawals
of strategic healthcare companies such as Jiangsu Hengrui
Med Co, Kangmei Pharmaceutical, Yunnan Baiyao Group
Co, Dong E E Jiao Co, Tasly Pharmaceutical, Shanghai
Raas Blood, Searainbow Hld Corp, Tonghua Dongbao
Pharma, Shanghai Fosun Pharma, Beijing Tongrentang
from western provinces deemed unprofitable albeit their
healthcare needs.
Inferring from our findings, we are disposed to agree
with [27] when they argue that while adequate regula-
tory framework is necessary to avoid over exploitation
by private investors in the healthcare sector in China,
some regulatory measures can bring unintended cost
and precipitate panic withdrawal and acquisition that
stimulates herding behavior and its consequences. In
reviewing the literature, we found out that recent pres-
sure on pharmaceutical and healthcare stocks in China
following the announcement by the China National De-
velopment and Reform Commission ordering price cuts
for certain drugs after a government reimbursement
scheme for some drugs was note well implemented. This
is what led to a sudden hike in the price of healthcare
products and subsequently healthcare stocks.
We recommend that future policies can be managed
through public-private consensus building and investor
sensitization than panic announcements.
Conclusions and future research direction
Within the limited number of studies on procyclical or
herding behavior in the healthcare sector in general and in
China in particular, our study sought to find out whether
herding syndromes exist among healthcare stock investors
and its implication for health equity in China and beyond.
We noted the prevalence of herding behavior in almost all
the healthcare sector in China using different testing
models. This is the first study to compare the effects of
different empirical models of herding in the healthcare
sector in China in its developing state. More importantly
the existence of herding behavior in the health stock
market provides significant implication for the healthcare
sector and healthcare delivery in China and beyondespecially for most countries that depend on China for
several medical services and equipments. We have ad-
equately discussed implications of the research for health
equity in China and beyond and made policy recommen-
dations. The results inspire curiosity on other remote fac-
tors that can trigger disequilibrium in the allocation of
healthcare resources in other emerging markets.
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